Work

Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.4515

Authors: Susan Halabi, Andrew J. Armstrong, A. Oliver Sartor, Johann Sebastian De Bono, Ellen B Kaplan, Eric Jay Small

Institutions: Duke Medical Center, Duke University, Duke Cancer Institute, Tulane University, Royal Marsden Hospital, University of California, San Francisco

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2596592750

Cites:

Cited by: 3

Related to: 10